Science
Unpredicted binding found between SARS-CoV-2 and hepatitis C drug, telaprevir – Drug Target Review
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Scientists have found new, unexpected behaviours when SARS-CoV-2 – the virus that causes COVID-19 – encounters drug inhibitors, which bind to certain components of the virus and block its ability to reproduce.
According to the team, from the US Department of Energy’s Oak Ridge National…
-
Noosa News23 hours agoBrisbane’s new bus timetable sees journey times decrease by two minutes in first three months
-
Noosa News22 hours agoCalls for greater education as growers in WA’s south-west brace for polyphagous shot-hole borer
-
Business22 hours agoWhat it means for shareholders
-
Business24 hours agoThe high-conviction ASX stocks I’d buy and hold forever